TITLE

Bevacizumab-based therapy for advanced small bowel adenocarcinoma

AUTHOR(S)
Tsang, H.; Yau, T.; Khong, P. L.; Epstein, R. J.
PUB. DATE
November 2008
SOURCE
Gut;Nov2008, Vol. 57 Issue 11, p1631
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented on the efficacy of treating Bevacizumab to patients with advanced small bowel adenocarcinoma.
ACCESSION #
35151095

 

Related Articles

  • Intravitreal bevacizumab and diabetic papillopathy with macular edema. Joob, Beuy; Wiwanitkit, Viroj // Oman Journal of Ophthalmology;Feb2012, Vol. 5 Issue 1, p68 

    A letter to the editor in response to the article "Diabetic papillopathy with macular edema treated with intravitreal bevacizumab," by A.S. Al-Hinai and colleagues is presented.

  • Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. Benoit, Amandine; Ducray, Fran�ois; Cartalat-Carel, St�phanie; Psimaras, Dimitri; Ricard, Damien; Honnorat, J�r�me // Journal of Neurology;Feb2011, Vol. 258 Issue 2, p328 

    A letter to the editor is presented which discusses a study regarding the positive therapeutic outcome of bevacizumab in a patient with brainstem radiation necrosis after a negative result of steroid treatment.

  • Low Dose of Bevacizumab Is Safe and Effective in Preventing Bleeding Episodes in Hereditary Hemorrhagic Telangiectasia. Lazaraki, Georgia; Akriviadis, Evangelos; Pilpilidis, Ioannis; Parisi, Ioanna; Tzilves, Dimitrios; Tarpangos, Anestis // American Journal of Gastroenterology;Dec2011, Vol. 106 Issue 12, p2204 

    A letter to the editor is presented in response to the article "Low Dose of Bevacizumab Is Safe and Effective in Preventing Bleeding Episodes in Hereditary Hemorrhagic Telangiectasia," by Georgia Lazaraki and colleagues that was published in a previous issue.

  • Comment on 'Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial'. Fayers, T. // Eye;Jun2011, Vol. 25 Issue 6, p820 

    A letter to the editor is presented in response to the article "Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial," by M. L. Subramanian and colleagues in the 2010 issue.

  • Reply to Chhablani. Forte, R.; Cennamo, G. L.; Finelli, M.; Farese, E.; D'Amico, G.; Nicoletti, G.; de Crecchio, G.; Cennamo, G. // Eye;Feb2011, Vol. 25 Issue 2, p254 

    A response by R. Forte and colleagues to a letter to the editor regarding their article "Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema" in the 2010 issue is presented.

  • A matter of public interest. Garattini, Silvio; Bertele, Vittorio // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/17/2010, Vol. 341 Issue 7764, p114 

    A letter to the editor is presented in response to the article "Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomized double masked study," by A. Tufail and colleagues in the June 10, 2010 issue.

  • Bevacizumab and the inverse postcode lottery. Harris, Matthew J. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/17/2010, Vol. 341 Issue 7764, p114 

    A letter to the editor is presented in response to the article "Bevacizumab for the treatment of neovascular age related macular degeneration," by U. Chakravarthy in the June 9, 2010 issue.

  • Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion: more data required. Hu, K.; Horgan, S. E.; Sivaraj, R. R.; Avgikos, K. // Eye;Jan2010, Vol. 24 Issue 1, p194 

    A letter to the editor is presented in response to the article "Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion: more data required," by Dr. K. Gündüz and Dr. S. J. Bakri .

  • Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Jalil, A.; Fenerty, C.; Charles, S. // Eye;Dec2007, Vol. 21 Issue 12, p1541 

    A letter to the editor is presented in response to an article about the impact of intravitreal bevacizumab on acute glaucoma which appeared in the December 2007 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics